# Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes

> **NCT06267391** · NA · RECRUITING · sponsor: **Endogenex, Inc.** · enrollment: 264 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus
- Type2diabetes
- Diabetes Mellitus, Type 2
- Diabetes
- Type 2 Diabetes

## Interventions

- **DEVICE:** ReCET Treatment
- **DEVICE:** Sham Procedure

## Key facts

- **NCT ID:** NCT06267391
- **Lead sponsor:** Endogenex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2026-10-01
- **Target enrollment:** 264 (ESTIMATED)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06267391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06267391, "Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06267391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*